Immunomodulating drugs used in the treatment of multiple sclerosis (Formulary)

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 10mg/mL (specialist use only)

Dosage:

See SMC advice 959/14.

Important: Formulation and dosage details

Formulation:

Tablets 10mg (specialist use only)

Dosage:

As per SMC 1300/18: treatment of adult patients with highly active relapsing multiple sclerosis
(MS) as defined by clinical or imaging features.

SMC restriction:

• Patients with rapidly evolving severe relapsing-remitting MS: patients with two or more relapses in the prior year whether on treatment or not, and at least one T1 gadolinium-enhancing lesion.
• Patients with sub-optimal therapy relapsing-remitting MS: patients with one or more relapses in the previous year while on disease modifying therapy, and at least one T1 gadolinium-enhancing lesion or nine T2 lesions. 

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Enteric coated capsules 120mg, 240mg (specialist use only)

Dosage:

See SMC advice 886/13. For advice on monitoring during and following treatment refer to SPC.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Tablets 10mg (specialist use only)

Dosage:

As per SMC 2253: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Capsules 500 micrograms (specialist use only)

Dosage:

See SMC advice 763/12.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection 20mg/mL (specialist use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection, pre-filled syringe 20mg/mL, 40mg/mL (specialist use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection beta-1a 22 micrograms (Rebif^®), 44 micrograms (Rebif^®), 30 micrograms (Avonex^®) (specialist use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection, beta-1b 300 micrograms (Betaferon^®), 300 micrograms (Extavia^®) (specialist use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for intravenous infusion 20mg/mL (specialist use only)

Dosage:

See SMC advice 329/06.

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 300mg (s)

Dosage:

As per SMC 2121: The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab.

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringe/pen 20mg/0·4mL (hospital use only)

Dosage:

The recommended dose is 20mg ofatumumab administered by subcutaneous injection with initial dosing at weeks 0, 1 and 2, followed by subsequent monthly dosing, starting at week 4.

See SMC advice 2357: treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

Important: Formulation and dosage details

Formulation:

Capsules 0·23mg and 0·46mg (starter packs) and 0.92mg (specialist use only)

Dosage:

See SMC advice 2309: treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
SMC restriction: suitable for or requesting an oral treatment.

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringes (beta-1a; Plegridy^®) 63 micrograms, 94 micrograms, 125 micrograms (specialist use only)

Dosage:

See SMC advice 1018/14. 

Important: Formulation and dosage details

Formulation:

Titration pack and film-coated tablets 20mg (under specialist direction only)

Dosage:

See SMC advice 2384: the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: Adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features, suitable for or requesting an oral treatment. 

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Tablet 0.25mg titration pack (specialist use only)

Dosage:

See SMC advice 2265.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Tablet 2mg (specialist use only)

Dosage:

As per SMC 2265: treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Tablets 14mg (specialist use only)

Dosage:

See SMC advice 940/14.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot